Skip to main content
Clinical Trials/NL-OMON45696
NL-OMON45696
Completed
Phase 4

The antibody response to pneumococcal vaccination in patients with inflammatory bowel disease patients treated with immunosuppressive agents - PNEUMOREACT

Academisch Medisch Centrum0 sites178 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
antibody response
Sponsor
Academisch Medisch Centrum
Enrollment
178
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Age \> 18 years old
  • \- On treatment with an immunosuppressive agent or planned treatment start with a TNF\-alpha inhibitor within 3 months after recruitment
  • \- Indication for pneumococcal vaccination (PCV13 plus PPV23\)
  • \- Able to give informed consent
  • \- Control group: diagnosed with IBD, not treated with immunosuppressives.

Exclusion Criteria

  • \- Diagnosis of an immune deficiency disorder
  • \- Age \< 18 years
  • \- Control group: treatment with immunosuppressive drugs

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Immune response test as new predictor for successful TKI stop in patients with chronic myeloid leukemiaChronic myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10009016Term: Chronic myeloid leukemia in remissionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2020-002850-26-NLAlbert Schweitzer Hospital57
Recruiting
Not Applicable
Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
NL-OMON55091Albert Schweitzer Ziekenhuis57
Recruiting
Not Applicable
De antistof respons na pneumokokkenvaccinatie bij IBD-patiënten die behandeld worden met immunosuppressiva – de PNEUMOREACT studieinflammatory bowel disease (inflammatoire darmziekte)immunosuppressive agents (immunosuppressiva)pneumococcal vaccination (pneumokokkenvaccinatie)vaccine immunogenicity (vaccin immunogeniciteit)
NL-OMON29135Academic Medical Center188
Completed
Phase 2
Antibody Response to Pneumococcal Vaccines PPV and PCV in Beta Thalassemia Major without SpleeBeta Thalassemia Major.Beta thalassaemia
IRCT201110116660N3Mazandaran University of Medical Sciences50
Active, not recruiting
Not Applicable
Serological response to antipneumococcal vaccination and consequent impact on Streptococcus pneumoniae nasal carriage in HIV positive adultsHIV positive adults with out previous PPV23 or PCV7 vaccinationMedDRA version: 14.1Level: LLTClassification code 10035652Term: Pneumococcus infection in conditions classified elsewhere and of unspecified siteSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2011-004518-40-ITAZIENDA OSPEDALIERA SENESE